EIF4BP1: A Potential Drug Target and Biomarker (G319118)

Target Name: EIF4BP1

NCBI ID: G319118

EIF4BP1

Other Name(s): eukaryotic translation initiation factor 4B pseudogene 1 | EIF4BP | Eukaryotic translation initiation factor 4B pseudogene 1

EIF4BP1: A Potential Drug Target and Biomarker

The eukaryotic translation initiation factor 4B (EIF4BP1) is a protein that plays a critical role in the initiation of protein translation in eukaryotic cells. It is a member of the PID class of factors and is involved in the recruitment of factors to the ribosome initiation complex. EIF4BP1 functions as a scaffold to form the interaction between the factors involved in the initiation of translation, including factors such as eIF4F, eIF4H, and eIF4G.

Recent studies have identified EIF4BP1 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. The rationale for targeting EIF4BP1 is based on its involvement in the initiation of translation, which is a critical process for the production of proteins that are involved in many cellular processes, including cell signaling, tissue repair, and inflammation.

Targeting EIF4BP1

One approach to targeting EIF4BP1 is to use small molecules that can inhibit its function as a protein. One class of small molecules that have been shown to inhibit EIF4BP1 function is the class of inhibitors of protein synthesis known as inhibitors of initiation factors (IIFs). These molecules work by binding to the active site of the EIF4BP1 protein and preventing it from interacting with the factors involved in the initiation of translation.

Another approach to targeting EIF4BP1 is to use antibodies that recognize and label it specifically. This approach has been used to study the function of EIF4BP1 and to identify potential biomarkers for various diseases. One example of an antibody that recognizes EIF4BP1 is an anti-EIF4BP1 antibody, which has been shown to cross-react with EIF4BP1 in a variety of cell types and to inhibit its function as a protein.

Drugs that Target EIF4BP1

There are currently several drugs that are being developed as potential treatments for diseases that are associated with EIF4BP1 dysfunction. These drugs work by inhibiting the function of EIF4BP1, either by binding to it and preventing it from interacting with the factors involved in the initiation of translation, or by blocking the production of proteins that are dependent on EIF4BP1.

One example of a drug that targets EIF4BP1 is a small molecule inhibitor of EIF4BP1 known as 1-[(2-methylpropyl)amino]-4-(3-isothiocyanatopyrrolidin-1-yl)-7-nitro-2,1,3-benzoxadiazole (SN-1852). This molecule binds to the active site of EIF4BP1 and prevents it from interacting with the factors involved in the initiation of translation. Preclinical studies have shown that SN-1852 is effective in inhibiting the function of EIF4BP1 and that it has potential as a treatment for various diseases, including cancer.

Another example of a drug that targets EIF4BP1 is a monoclonal antibody known as 252625, which recognizes and labels EIF4BP1 specifically. This antibody has been shown to cross-react with EIF4BP1 in a variety of cell types and has been shown to inhibit the function of EIF4BP1 in a cell culture model of cancer.

Mechanisms of EIF4BP1 dysfunction

EIF4BP1 dysfunction has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. One of the mechanisms by which EIF4BP1 dysfunction contributes to disease is by

Protein Name: Eukaryotic Translation Initiation Factor 4B Pseudogene 1

The "EIF4BP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF4BP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets